Hannah Smith

Dr. Hannah Smith

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2024 in Cells
Verified
Journal Article
Open access
PDF file
HSHannah Smith
Hannah Smith
BGBethany Goodlett
Bethany Goodlett
SNShobana Navaneethabalakrishnan
Shobana Navaneethabalakrishnan
Brett M MitchellBrett M Mitchell
Brett M Mitchell
Hypertension (HTN) impacts almost half of adults, predisposing them to cardiovascular disease and renal damage. Salt-sensitive HTN (SSHTN) and angiotensin II (A2)-induced HTN (A2HTN) both involve immune system activation and renal innate immune cell infiltration. Subpopulations of activated [Cluster of differentiation 38 (CD38)] innate immune cells, such as macrophages and dendritic cells (DCs), play distinct roles in modulating renal function and blood pressure. It is unknown how these cells become CD38+ or which subtypes are pro-hypertensive. When bone marrow-derived monocytes (BMDMs) were grown in granulocyte-macrophage colony stimulating factor (GM-CSF) and treated with salt or A2, CD38+ macrophages and CD38+ DCs increased. The adoptive transfer of GM-CSF-primed BMDMs into mice with either SSHTN or A2HTN increased renal CD38+ macrophages and CD38+ DCs. Flow cytometry revealed increased renal M1 macrophages and type-2 conventional DCs (cDC2s), along with their CD38+ counterparts, in mice with either SSHTN or A2HTN. These results were replicable in vitro. Either salt or A2 treatment of GM-CSF-primed BMDMs significantly increased bone marrow-derived (BMD)-M1 macrophages, CD38+ BMD-M1 macrophages, BMD-cDC2s, and CD38+ BMD-cDC2s. Overall, these data suggest that GM-CSF is necessary for the salt or A2 induction of CD38+ innate immune cells, and that CD38 distinguishes pro-hypertensive immune cells. Further investigation of CD38+ M1 macrophages and CD38+ cDC2s could provide new therapeutic targets for both SSHTN and A2HTN.

23 June 2025 in Clinical Science
Verified
Journal Article
Open access
SKSunitha Konatham
Sunitha Konatham
BGBethany Goodlett
Bethany Goodlett
HSHannah Smith
Hannah Smith
Brett M MitchellBrett M Mitchell
Brett M Mitchell
Hypertension affects nearly one in two American adults and is a major risk factor for cardiovascular events and organ damage. Many treatments exist to lower blood pressure in hypertensive patients; however, their degree of effectiveness varies. It is well known that the pathology of hypertension is interwoven with actions of the immune system. Different types of immune cells infiltrate and accumulate in organs under hypertensive conditions and contribute to cytokine release and persistent inflammation. Recently, it has been shown that blood pressure can be lowered by increasing renal-specific lymphangiogenesis, which facilitates the movement of immune cells out of the kidneys. Hypertension is known to be correlated with increased lymphangiogenesis in tissues including the kidneys, heart, gonads, and skin; however, little is known about this relationship. In this brief review article, we explore the connections between hypertension, a well-studied disease, and the lymphatic system, a historically understudied system. We speculate on points of relation and the potential impact of lymphatic-focused hypertension treatments.

10 December 2025 in Clinical Science
Verified
Journal Article
Open access
SNShobana Navaneethabalakrishnan
Shobana Navaneethabalakrishnan
BGBethany Goodlett
Bethany Goodlett
HSHannah Smith
Hannah Smith
ACAlyssa Cardenas
Alyssa Cardenas
RIRobert A. Montalvo Ii
Robert A. Montalvo Ii
Brett M MitchellBrett M Mitchell
Brett M Mitchell
Salt-sensitive hypertension (SSHTN) promotes systemic inflammation, pro-inflammatory immune cell infiltration, and end-organ damage, including in the kidneys and gonads. However, its impact on uterine immune cell populations remains unclear. We hypothesized that SSHTN alters immune cell homeostasis, induces inflammation, and promotes lymphangiogenesis in the uterus, and that these effects can be mitigated by pharmacological blood pressure (BP) reduction and anti-inflammatory macrophage augmentation. To test the hypothesis, female C57BL6/J mice were given nitro-L-arginine methyl ester hydrochloride (0.5 mg/ml) in drinking water for 2 weeks, followed by a 2-week washout period. Mice were then subjected to a 4% high-salt diet (SSHTN) for 3 weeks. Another group of mice received either hydralazine (HYD; 250 mg/l in drinking water), a vasodilator (SSHTN+HYD), or AVE0991 (AVE; 0.58 µmol/kg body weight/day), a nonpeptide Mas receptor agonist, through daily intraperitoneal injections (SSHTN+AVE). Control mice received tap water and a standard diet for the entire treatment period. Flow cytometry data revealed a significant decrease in total uterine CD45+ immune cells, along with an increase in tissue macrophages, in all SSHTN groups compared with the control group. SSHTN mice had increased uterine pro-inflammatory macrophages, dendritic cells, natural killer cells, and CD4+ pro-inflammatory T cells, all of which were mitigated by HYD and AVE treatments. SSHTN promoted uterine inflammation, lymphatic vessel expansion, and altered hormone receptor expression, which were mitigated by pharmacological intervention, highlighting their therapeutic potential in preserving uterine homeostasis and improving reproductive health in women with SSHTN.

24 July 2025 in Cells
Verified
Journal Article
Open access
PDF file
HSHannah Smith
Hannah Smith
BGBethany Goodlett
Bethany Goodlett
GPGabriella Peterson
Gabriella Peterson
EZEmily N. Zamora
Emily N. Zamora
Ava Rae GostomskiAva Rae Gostomski
Ava Rae Gostomski
Brett M MitchellBrett M Mitchell
Brett M Mitchell
Hypertension (HTN) is a major contributor to global morbidity and manifests in several variants, including salt-sensitive hypertension (SSHTN). SSHTN is defined by an increase in blood pressure (BP) in response to high dietary salt, and is associated with heightened cardiovascular risk, renal damage, and immune system activation. However, the role of granulocyte-macrophage colony-stimulating factor (GM-CSF) has not yet been explored in the context of SSHTN. Previously, we reported that GM-CSF is critical in priming bone marrow-derived (BMD)-macrophages (BMD-Macs) and BMD-dendritic cells (BMD-DCs) to become activated (CD38+) in response to salt. Further exploration revealed these cells differentiated into BMD-M1 Macs, CD38+ BMD-M1 Macs, BMD-type-2 conventional DCs (cDC2s), and CD38+ BMD-cDC2s. Additionally, BMD-monocytes (BMDMs) grown with GM-CSF and injected into SSHTN mice traffic to the kidneys and differentiate into Macs, CD38+ Macs, DCs, and CD38+ DCs. In the current study, we treated SSHTN mice with an anti-GM-CSF antibody (aGM) and found that preventive aGM treatment mitigated BP, prevented renal inflammation, and altered renal immune cells. In mice with established SSHTN, aGM treatment attenuated BP, reduced renal inflammation, and differentially affected renal immune cells. Adoptive transfer of aGM-treated BMDMs into SSHTN mice resulted in decreased renal trafficking. Additionally, aGM treatment of BMD-Macs, CD38+ BMD-M1 Macs, BMD-DCs, and CD38+ BMD-cDC2s led to decreased pro-inflammatory gene expression. These findings suggest that GM-CSF plays a role in SSHTN and may serve as a potential therapeutic target.